Protalix Biotherapeutics, Inc. (PLX)
2.73
+0.02
(+0.74%)
USD |
NYAM |
Oct 06, 16:00
2.725
0.00 (0.00%)
Pre-Market: 20:00
Protalix Biotherapeutics Profit Margin (Quarterly) : 18.98% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.98% |
| March 31, 2026 | 54.27% |
| December 31, 2025 | -60.34% |
| September 30, 2025 | 13.19% |
| June 30, 2025 | 1.05% |
| March 31, 2025 | -35.79% |
| December 31, 2024 | 35.65% |
| September 30, 2024 | 18.02% |
| June 30, 2024 | -16.35% |
| March 31, 2024 | -122.6% |
| December 31, 2023 | -57.64% |
| September 30, 2023 | -17.90% |
| June 30, 2023 | 55.14% |
| March 31, 2023 | -32.66% |
| December 31, 2022 | -43.40% |
| September 30, 2022 | -25.15% |
| June 30, 2022 | -60.94% |
| March 31, 2022 | -14.21% |
| December 31, 2021 | -77.99% |
| September 30, 2021 | -34.83% |
| June 30, 2021 | -174.9% |
| March 31, 2021 | -48.37% |
| December 31, 2020 | 2.04% |
| September 30, 2020 | -41.12% |
| June 30, 2020 | -37.84% |
| Date | Value |
|---|---|
| March 31, 2020 | 7.70% |
| December 31, 2019 | 1.64% |
| September 30, 2019 | -24.99% |
| June 30, 2019 | -63.22% |
| March 31, 2019 | -69.59% |
| December 31, 2018 | -52.49% |
| September 30, 2018 | -43.15% |
| June 30, 2018 | -174.9% |
| March 31, 2018 | -206.5% |
| December 31, 2017 | -613.2% |
| September 30, 2017 | -152.0% |
| June 30, 2017 | 7.08% |
| March 31, 2017 | -2.05K% |
| December 31, 2016 | -126.1% |
| September 30, 2016 | -156.1% |
| June 30, 2016 | -606.9% |
| March 31, 2016 | -1.26K% |
| September 30, 2015 | -65.34% |
| June 30, 2015 | -109.9% |
| March 31, 2015 | -117.2% |
| December 31, 2014 | -611.9% |
| September 30, 2014 | -216.1% |
| June 30, 2014 | -227.8% |
| March 31, 2014 | -99.49% |
| December 31, 2013 | -970.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Taysha Gene Therapies, Inc. | -- |
| Humacyte, Inc. | -9.06K% |
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 32.70% |
| Return on Assets | 20.78% |
| Return on Invested Capital | 28.77% |
| Gross Profit Margin (Quarterly) | 60.99% |
| Operating Margin (Quarterly) | 23.48% |
| Return on Net Operating Assets | 38.68% |